MCM Vaccines

Focus: MCM Vaccines is a Netherlands-based biotechnology company specializing in combination vaccines targeting infectious diseases. The company operates at a smaller scale with a focused pipeline in vaccine development and infectious disease therapeutics.

Infectious Diseases Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About MCM Vaccines

AI assessmentNot Hiring

No open roles listed right now. Follow MCM Vaccines to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

11 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Human Papillomavirus and Pregnancy

HPV-infection in Pregnant Women

N/A

Clinical Trials (1)

NCT01897129Human Papillomavirus and Pregnancy

N/A

Help build intelligence for MCM Vaccines

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage vaccine specialist with 23 active pipeline programs across multiple infectious disease indications (tetanus, rotavirus, meningococcal, HPV, hepatitis B, influenza, HIV)
Located in Leiden, Netherlands—a global vaccine development hub with access to specialized talent and research infrastructure
Focused therapeutic niche (combination vaccines and infectious diseases) offers deep domain expertise opportunity versus generalist pharma roles

Watch Out For

Zero active job openings reported and no hiring data available, suggesting minimal near-term growth or recruitment activity
Pre-revenue biotech status with no disclosed funding, financials, or revenue concentration metrics creates uncertainty around runway and stability
No published research output (0 publications), limited clinical trial activity (15 total trials), and scattered pipeline focus across unrelated indications suggests potential resource constraints or portfolio management challenges

Generated by Claude from MCM Vaccines's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Lixisenatide

Diabetes After Total Pancreatectomy

N/A

Clinical Trials (1)

NCT02640118The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects

N/A

High-Dose trivalent inactivated influenza vaccine

Pediatric Solid Organ Transplant Patients

Phase 1

Clinical Trials (1)

NCT01525004Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients

Phase 1

Vaxigrip® trivalent inactivated influenza vaccine

Influenza

Phase 1/2

Clinical Trials (1)

NCT00386542Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children

Phase 1/2

CMV gB vaccine

Cytomegalovirus Infections

Phase 2

Clinical Trials (1)

NCT00125502Recombinant CMV gB Vaccine in Postpartum Women

Phase 2

Non-adjuvanted A

Influenza

Phase 2

Clinical Trials (1)

NCT01024400Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women

Phase 2

inactivated non adjuvanted pandemic H1N1 vaccine

Renal Transplant Recipients

Phase 2

Clinical Trials (1)

NCT01086904Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients

Phase 2

GenHevac-B

Hepatitis B

Phase 3

Clinical Trials (1)

NCT00670839Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)

Phase 3

ALVAC-HIV vCP1521 + AIDSVAX

HIV Infection

Phase 3

Clinical Trials (1)

NCT00223080HIV Vaccine Trial in Thai Adults

Phase 3

Pediacel® and Infanrix™-IPV/Hib

Infant Immunizations

Phase 3

Clinical Trials (1)

NCT00990080Interchangeability of Infanrix™ IPV/Hib and Pediacel® at 2,4 & 6 Months of Age

Phase 3

GenHevac B Pasteur

HIV Infections

Phase 3

Clinical Trials (1)

NCT00480792Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients

Phase 3

Blood Sample

Hepatitis B

Phase 3

V419

Neisseria Meningitidis

Phase 3

Clinical Trials (1)

NCT01553279Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

Phase 3

Rotateq vaccine

Rotavirus Gastroenteritis

Phase 4

Clinical Trials (1)

NCT00740935Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France.

Phase 4

Intanza

Influenza

Phase 4

Clinical Trials (1)

NCT01224613Study to Compare Self-administered and Nurse-administered Intradermal Influenza Vaccine

Phase 4

Td5ap

Tetanus

Phase 4

Clinical Trials (1)

NCT00870350An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster